[Elsevier] Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial |
|
This post will be closed automatically in 2026-08-29 21:24
Reward20points
|
post
reply
points
2871
50
Combination therapy in metabolic dysfunction-associated steatohepatitis
10
Therapeutic importance of Cucurbitaceae: A medicinally important family
30
Factors associated with pessary discontinuation in women with pelvic organ prolapse: A retrospective observational study
10
RIFM fragrance ingredient safety assessment, 2-methoxy-4-methylphenol, CAS Registry Number 93-51-6
10
Multivalent metal catalysts in Fenton/Fenton-like oxidation system: A critical review
